Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | SMC2 | O95347 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.34 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138094 | 0.81 | MEN1 (0.43) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137838 | 0.79 | MEN1 (0.36) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL6137572 | 0.79 | MAP2K1 (0.40) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL5742416 | 0.77 | MAP2K1 (0.48) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL6137573 | 0.76 | MEN1 (0.36) | MAP2K1MAP2K2IDO1MEN1KMT2A | |
| SCHEMBL14590619 | 0.76 | MAP2K1 (0.49) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL14590598 | 0.76 | MAP2K1 (0.43) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL14590630 | 0.75 | MAP2K1 (0.42) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL14590613 | 0.74 | MAP2K1 (0.54) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL14590595 | 0.73 | MAP2K1 (0.44) | MAP2K1MAP2K2ABCB11NQO2SMC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1651214-A2 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY | 2005-02-03 | — | — | US | disclosed |
| WO-2005009975-A2 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | CYP3A5, CYP3A7, UGT2B7 | MAP2K1 4401/4885MAP2K2 4101/4885ABCB11 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.